Revolo Biotherapeutics is accelerating development of its oral allergy drug, ‘1104. Clinical trials start in 2026. 💊
#News #Biotech #AllergyTreatment #Immunotherapy #ClinicalTrials #EosinophilicEsophagitis #AtopicDermatitis #Revolo1104 #HealthcareInnovation #DrugDevelopment #Biopharma
#News #Biotech #AllergyTreatment #Immunotherapy #ClinicalTrials #EosinophilicEsophagitis #AtopicDermatitis #Revolo1104 #HealthcareInnovation #DrugDevelopment #Biopharma
Revolo fast-tracks oral drug for allergic diseases after promising results
The company’s peptide therapy, '1104, shows promise as an oral treatment for allergic diseases, with clinical trials expected to begin in 2026.
druganddeviceworld.com
August 7, 2025 at 9:24 AM
Everybody can reply
Revolo Biotherapeutics is accelerating development of its oral allergy drug, ‘1104. Clinical trials start in 2026. 💊
#News #Biotech #AllergyTreatment #Immunotherapy #ClinicalTrials #EosinophilicEsophagitis #AtopicDermatitis #Revolo1104 #HealthcareInnovation #DrugDevelopment #Biopharma
#News #Biotech #AllergyTreatment #Immunotherapy #ClinicalTrials #EosinophilicEsophagitis #AtopicDermatitis #Revolo1104 #HealthcareInnovation #DrugDevelopment #Biopharma
Revolo fast-tracks oral drug for allergic diseases after promising results
The company’s peptide therapy, '1104, shows promise as an oral treatment for allergic diseases, with clinical trials expected to begin in 2026.
druganddeviceworld.com
August 7, 2025 at 9:24 AM
Everybody can reply